BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 –23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care.
The conference comes at a critical point in the history of cystic fibrosis, a fatal genetic disease that causes life-threatening lung infections and premature death. For the first time, drugs that treat the underlying cause of the disease have reached the final stages of clinical testing. Up to now, only drugs that treat the symptoms of CF have been available to patients. Therapies in Phase 3 include: ataluren, Bronchitol, denufosol, and VX-770.
Key topics of the conference include:
- Attacking the core defect in CF from every angle;
- The power of patient and family involvement in improving care;
- Grappling with adult issues as people with CF live increasingly longer; and
- Advancements in inhaled antibiotics for CF.
An estimated 30,000 people in the United States have cystic fibrosis, and about 70,000 people worldwide. Ten million Americans are unknowing carriers of a defective CF gene. Fifty years ago, most children with CF died before reaching kindergarten. Today, because of Cystic Fibrosis Foundation-supported drug research and care, people with CF are living into their 30s, 40s and beyond.
The 24th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.
WHEN & WHERE:
Thursday, Oct. 21 - Saturday, Oct. 23, 2010, at the Baltimore Convention Center, Baltimore, Maryland
- Thurs., Oct. 21 at 4:20 p.m. – "Pipeline: Airway
Surface Liquid Modulation</